Condition: Asthma
Intervention: Drug: ABS eMDPI
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Drug: ABS eMDPI
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Predictive Properties of the Asthma Control Test and Its Component Questions for Severe Asthma Exacerbations.
J Allergy Clin Immunol Pract. 2016 Aug 17;
Authors: Cajigal S, Wells KE, Peterson EL, Ahmedani BK, Yang JJ, Kumar R, Burchard EG, Williams LK
Abstract
BACKGROUND: Current US guidelines recommend the Asthma Control Test (ACT) for assessing disease control and selecting treatment.
OBJECTIVE: The goal of this study was to prospectively assess the ACT and its component questions for their utility in predicting the risk of severe asthma exacerbations.
METHODS: Individuals were participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity, and those included in the current analysis had the following characteristics: age 18 years or more, physician-diagnosed asthma, and longitudinal care received at a large health system in southeastern Michigan. Study participants underwent a baseline evaluation, which included answering the ACT. A severe asthma exacerbation was defined as one requiring oral steroids, an emergency department visit, or inpatient admission. Receiver-operator characteristic curves were used to measure and compare the predictive utility of the ACT and its component questions for severe asthma exacerbations.
RESULTS: Of 1180 participants, 354 (30.0%) experienced a severe asthma exacerbation within 6 months of their baseline evaluation. When compared with the individual questions that composed the ACT, the composite score was significantly better at predicting severe exacerbations with 1 exception; the composite ACT score and the question assessing rescue medication use were not significantly different (P = .580). Pharmacy-based records of metered-dose inhaler short-acting beta-agonist use and asthma severity were also not significantly different from the composite ACT score.
CONCLUSIONS: Our study demonstrates that although the ACT is modestly predictive for exacerbations, the composite score may not be superior to assessing rescue medication use alone for predicting the risk of severe asthma exacerbations.
PMID: 27544712 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Sporadic Steroids May Lessen Asthma Exacerbations For Peds
Monthly Prescribing Reference (registration) HealthDay News — There is strong evidence to support intermittent inhaled corticosteroids (ICS) for prevention of wheeze exacerbations in preschool children with intermittent asthma or viral-triggered wheezing, according to a review published online … |
View full post on asthma – Google News
Impacts of coexisting bronchial asthma on severe exacerbations in mild | COPD
Dove Medical Press Backround: Acute exacerbations are major drivers of COPD deterioration. However, limited data are available for the prevalence of severe exacerbations and impact of asthma on severe exacerbations, especially in patients with mild-to-moderate COPD. |
View full post on asthma – Google News
Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children
Dove Medical Press Background: Non-adherence to inhaled corticosteroids (ICSs) is a major risk factor for poor asthma control in children. However, little is known about the effect of adherence to ICS on the incidence of asthma exacerbations. The objective of this study … |
View full post on asthma – Google News
Angiopoietin-2 linked to severe asthma, exacerbations
Healio Patients with increased Angiopoietin-2 serum levels are more likely to have severe or refractory asthma and have repeat severe exacerbations, according to research. “Our study has confirmed and extended previous observations suggesting an imbalance … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: vitamin D3 4000 IU; Drug: Placebo
Sponsors: University of Pittsburgh; Pharmavite; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting – verified February 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Study explores new approaches to prevent fall asthma exacerbations in …
News-Medical.net Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients. Their findings were released online in late October and published in … |
View full post on asthma – Google News
EurekAlert (press release) |
New research on preventing fall asthma exacerbations
EurekAlert (press release) Aurora, Colo. (Jan. 14, 2016) – Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients. Their findings were released online in … |
View full post on asthma – Google News
Predicting frequent asthma exacerbations using blood eosinophil count and …
Dove Medical Press Patients and methods: Medical records of 130,547 asthma patients aged 12–80 years from the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 1990–2013, were examined for 1 year before (baseline) and 1 year after … |
View full post on asthma – Google News